Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Parkin does not prevent accelerated cardiac aging in mitochondrial DNA mutator mice
Benjamin P. Woodall, … , Anne N. Murphy, Åsa B. Gustafsson
Benjamin P. Woodall, … , Anne N. Murphy, Åsa B. Gustafsson
Published April 16, 2019
Citation Information: JCI Insight. 2019;4(10):e127713. https://doi.org/10.1172/jci.insight.127713.
View: Text | PDF
Research Article Cardiology Cell biology

Parkin does not prevent accelerated cardiac aging in mitochondrial DNA mutator mice

  • Text
  • PDF
Abstract

The E3 ubiquitin ligase Parkin plays an important role in regulating clearance of dysfunctional or unwanted mitochondria in tissues, including the heart. However, whether Parkin also functions to prevent cardiac aging by maintaining a healthy population of mitochondria is still unclear. Here, we have examined the role of Parkin in the context of mitochondrial DNA (mtDNA) damage and myocardial aging using a mouse model carrying a proofreading-defective mtDNA polymerase γ (POLG). We observed both decreased Parkin protein levels and development of cardiac hypertrophy in POLG hearts with age; however, cardiac hypertrophy in POLG mice was neither rescued, nor worsened by cardiac-specific overexpression or global deletion of Parkin, respectively. Unexpectedly, mitochondrial fitness did not substantially decline with age in POLG mice when compared with that in WT mice. We found that baseline mitophagy receptor–mediated mitochondrial turnover and biogenesis were enhanced in aged POLG hearts. We also observed the presence of megamitochondria in aged POLG hearts. Thus, these processes may limit the accumulation of dysfunctional mitochondria as well as the degree of cardiac functional impairment in the aging POLG heart. Overall, our results demonstrate that Parkin is dispensable for constitutive mitochondrial quality control in a mtDNA mutation model of cardiac aging.

Authors

Benjamin P. Woodall, Amabel M. Orogo, Rita H. Najor, Melissa Q. Cortez, Eileen R. Moreno, Hongxia Wang, Ajit S. Divakaruni, Anne N. Murphy, Åsa B. Gustafsson

×

Figure 2

Characterization of Parkin expression and mitophagy in WT and POLG mice at 6 months of age.

Options: View larger image (or click on image) Download as PowerPoint
Characterization of Parkin expression and mitophagy in WT and POLG mice ...
(A) Real-time qPCR analysis of Park2 (Parkin) transcript levels (n = 3). (B) Representative Western blots and quantitation of Parkin in whole heart lysates and isolated mitochondrial fractions prepared from WT and POLG hearts (n = 3). (C) Representative Western blot and quantitation of Parkin in heart lysates prepared from WT, POLG, mCAT-transgenic, and POLG+mCAT-transgenic mice. mCAT, mitochondrial-targeted catalase (n = 3–5). Assessment of mitochondrial recruitment of Parkin in isolated myocytes from 6-month-old WT and POLG mice following treatment with rotenone (40 μM, 60 minutes). (D) Representative images of mCherry-Parkin and mitochondria stained with anti-Tom20 demonstrate translocation of Parkin to mitochondria in both WT and POLG myocytes after rotenone treatment. Scale bar: 20 μm. Original magnification ×63. (F) Line scan analysis using ImageJ software confirmed colocalization between mCherry-Parkin (red) and mitochondria (Tom20, green) after exposure to rotenone. Data are mean ± SEM (*P < 0.05; **P < 0.01). Statistical analysis was performed using Student’s t test or ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts